FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2502113158> ?p ?o ?g. }

• W2502113158 abstract "Background: Pegcantratinib is the first topically applied tropomyosin receptor kinase inhibitor allowing retention in the skin to exert its effects at nanomolar concentrations. Pegcantratinib is now under early clinical evaluation as an anti-tumour agent in patients with germline mutations in the tumour suppressor gene CYLD, which include multiple clinical presentations of rare, skin appendage tumours. No pharmacological treatment is currently available and patients face repeated and disfiguring surgery to control tumour burden. We report on the development and validation of an analytical method to quantify pegcantratinib in skin tumour biopsies of patients to determine tumour penetration. Methods: A sensitive and specific HPLC-MS/MS (API 4000) assay coupled with in-source CID was developed and validated according to EMA guidelines, for direct quantitative measurement of pegcantratinib in biopsies of human skin tumours. The sample preparation procedure required a 10 mg sample volume and involved protein precipitation with acetonitrile following tissue homogenization and addition of internal standard. Reversed-phase chromatography under gradient conditions (MP A - 1% formic acid; MP B - 1% formic acid in acetonitrile) was applied with separation on a Kinetex 2.6 μm C18 column (100 A, 50 × 4.6 mm). Detection was obtained by SRM, following the transitions m/z 419.0 → 376.4. The method is rapid and selective, allowing good resolution of peaks in 2.4 min. Results: The assay was fully validated and the method exhibited good sensitivity, precision, and accuracy, with overall precision expressed as CV ≤8.5% and accuracy in the range 96-99%. Recovery was high (≥85%) and consistent with CV ≤13%. No matrix effect was observed in four independent matrix sources including 3 different tumours and normal skin, the calculated CV was 5%. The limit of quantitation was 2.5 ng/ml, with precision and accuracy of 6% and 99%, respectively. The assay developed was linear in the range 1.0-500 ng/ml, with mean precision Conclusion: We have successfully developed a LC-MS/MS method to measure the anti-tumour agent pegcantratinib in human skin tumour samples. Analysis of samples obtained from the Phase 1b/2a clinical trial is now underway. Acknowledgements: Work supported by the Department of Health and Wellcome Trust through the Health Innovation Challenge Fund and Cancer Research UK. Citation Format: Monique Zangarini, Neil Rajan, Marina Danilenko, Philip Berry, Gareth J. Veal. Development and validation of a LC-MS/MS method for the quantification of the tropomyosin receptor kinase (Trk) inhibitor pegcantratinib in human skin tumors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 333." @default.
• W2502113158 created "2016-08-23" @default.
• W2502113158 creator A5012435189 @default.
• W2502113158 creator A5020692726 @default.
• W2502113158 creator A5040899654 @default.
• W2502113158 creator A5062338155 @default.
• W2502113158 creator A5091131903 @default.
• W2502113158 date "2016-07-15" @default.
• W2502113158 modified "2023-09-27" @default.
• W2502113158 title "Abstract 333: Development and validation of a LC-MS/MS method for the quantification of the tropomyosin receptor kinase (Trk) inhibitor pegcantratinib in human skin tumors" @default.
• W2502113158 doi "https://doi.org/10.1158/1538-7445.am2016-333" @default.
• W2502113158 hasPublicationYear "2016" @default.
• W2502113158 type Work @default.
• W2502113158 sameAs 2502113158 @default.
• W2502113158 citedByCount "0" @default.
• W2502113158 crossrefType "proceedings-article" @default.
• W2502113158 hasAuthorship W2502113158A5012435189 @default.
• W2502113158 hasAuthorship W2502113158A5020692726 @default.
• W2502113158 hasAuthorship W2502113158A5040899654 @default.
• W2502113158 hasAuthorship W2502113158A5062338155 @default.
• W2502113158 hasAuthorship W2502113158A5091131903 @default.
• W2502113158 hasConcept C179998833 @default.
• W2502113158 hasConcept C185592680 @default.
• W2502113158 hasConcept C2777379063 @default.
• W2502113158 hasConcept C43617362 @default.
• W2502113158 hasConcept C74774607 @default.
• W2502113158 hasConceptScore W2502113158C179998833 @default.
• W2502113158 hasConceptScore W2502113158C185592680 @default.
• W2502113158 hasConceptScore W2502113158C2777379063 @default.
• W2502113158 hasConceptScore W2502113158C43617362 @default.
• W2502113158 hasConceptScore W2502113158C74774607 @default.
• W2502113158 hasLocation W25021131581 @default.
• W2502113158 hasOpenAccess W2502113158 @default.
• W2502113158 hasPrimaryLocation W25021131581 @default.
• W2502113158 hasRelatedWork W1007088450 @default.
• W2502113158 hasRelatedWork W1523795825 @default.
• W2502113158 hasRelatedWork W2020238683 @default.
• W2502113158 hasRelatedWork W2028458952 @default.
• W2502113158 hasRelatedWork W2030296316 @default.
• W2502113158 hasRelatedWork W2055962979 @default.
• W2502113158 hasRelatedWork W2061543452 @default.
• W2502113158 hasRelatedWork W2073376096 @default.
• W2502113158 hasRelatedWork W2133090912 @default.
• W2502113158 hasRelatedWork W2141696718 @default.
• W2502113158 hasRelatedWork W2286271559 @default.
• W2502113158 hasRelatedWork W2328231387 @default.
• W2502113158 hasRelatedWork W2581034521 @default.
• W2502113158 hasRelatedWork W2975677693 @default.
• W2502113158 hasRelatedWork W2980405084 @default.
• W2502113158 hasRelatedWork W2999597537 @default.
• W2502113158 hasRelatedWork W3025747775 @default.
• W2502113158 hasRelatedWork W3126231756 @default.
• W2502113158 hasRelatedWork W3210365803 @default.
• W2502113158 hasRelatedWork W2800326925 @default.
• W2502113158 isParatext "false" @default.
• W2502113158 isRetracted "false" @default.
• W2502113158 magId "2502113158" @default.
• W2502113158 workType "article" @default.